g Rec'd PCT/PTO 0 7 JUN 2001 OCKET NO. BM45339 09/857669

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

## BOX PCT/DO-EO

Commissioner for Patents Washington, D.C. 20231

"Express Mail" mailing label number ET 383 023 345 US

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 CFR § 1.10 on the date indicated above and addressed to: Commissioner of Patents, Washington, DC 20231, on June 7, 2091.

NATIONAL STAGE APPLICATION TRANSMITTAL LETTER

Transmitted herewith for filing is the patent application of:

Inventor(s)/Applicant(s):

Ruelle, Jean-Louis

Colleen Hanagan

**International Application No.:** 

PCT/EP99/09560

International Published Appln. No.: WO 00/34480

APPLICATION FILING UNDER 35 U.S.C. § 371

**International Filing Date:** 

**02 December 1999** 

**Priority Filing Date:** 

**07 December 1998** 

**Thirty Month Date:** 

07 June 2001

Title:

"POLYPEPTIDES AND POLYNUCLEOTIDES

BASB040 FROM NEISSERIA MENINGITIDIS

AND VACCINE COMPRISING SAID

POLYPEPTIDES AND POLYNUCLEOTIDES"


THIS NEW APPLICATION IS A NATIONAL STAGE APPLICATION UNDER PCT, CHAPTER II WITH A REQUEST FOR **EXAMINATION WITHOUT DELAY TO THE UNITED STATES** DESIGNATED/ELECTED OFFICE (DO/EO/US).

> This is a FIRST submission of items concerning a filing under 35 U.S.C. § 371;

This is a SECOND or subsequent submission of items concerning a filing under 35 U.S.C. § 371.

This is an express request to begin national examination procedures (35 U.S.C. 2. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).





month from the earliest claimed priority date.		
4. Enclosed items are required for filing under 37 CFR § 1.53(b) and § 1.494(b) or § 1.495(b):		
	$\boxtimes$	One copy of International Publication No. WO 00/34480
	(a)	is transmitted herewith (required only if not transmitted by the International Bureau)
	(b)	has been transmitted by the International Bureau
	(c)	is not required, as the application was filed in the United States Receiving Office (RO/US)
<u>Fees</u>		
The basic national fee set forth in 37 CFR § 1.482 - International Preliminary Examination Fee not paid to USPTO but International Search Report prepared by the EPO or JPO - \$860.00		
	$\boxtimes$	Claims in Excess of 20 (7 @ \$18.00)
	$\boxtimes$	Independent Claims in Excess of 3 (1 @ \$80.00)
5.	Further enclosed are:	
	$\boxtimes$	One copy of International Preliminary Examination Report.
	$\boxtimes$	One copy of International Search Report.
		One copy of Written Opinion.
		One copy of PCT Request as filed.
		One copy of Chapter II Demand as filed.
6. 371(c	(2))	A translation of the International Application into English (35 U.S.C. §
7. 19 (3	 5 U.S.C.	Amendments to the claims of the International Application under PCT Article § 371(c)(3))
8. § 371	(c)(3))	A translation of the amendments to the claims under PCT Article 19 (35 U.S.C.
9. Still additional papers enclosed:		
		Assignment with Assignment Recordation Form Cover Sheet
		Verification Statement Claiming Small Entity Status
		Declaration or oath is enclosed executed by the inventor
		An Information Disclosure Statement under 37 CFR § 1.97 and § 1.98
	$\boxtimes$	Return Acknowledgment Postcard

11.

П



Nucleotide and/or Amino Acid Sequence Submission (if applicable, all 10. necessary) Enclosed are: Α. Computer Readable Copy of the Sequence Listing (a) (b) Paper Copy (identical to Computer Readable Copy) of the Sequence Listing B. Enclosed is a paper copy of the Sequence Listing. This paper copy and a Computer Readable Form thereof are identical with the Computer Readable Form in another application of the Applicant which is fully identified as follows: U.S. Application No.: @@ Filed: @@ Attorney Docket No.: @@ which is believed to comply with the rules set forth in 37 CFR § 1.821 et. seq. Applicants requests pursuant to 37 CFR § 1.821(e) that this Computer Readable Form be used in the present application. Please TRANSFER the sequence listing from the parent to this application. C. Statement under 37 CFR § 1.821(f): The information recorded in computer readable form is identical to the written Sequence Listing. D. Statement under 37 CFR § 1.821(g) (required when Sequence Listing not submitted at the time of filing under 35 U.S.C. §111(a)) or 37 CFR §1.821(f) (required when Sequence Listing not submitted at the time of filing under the Patent Cooperation Treaty): The submission of the Sequence Listing includes no new matter. E. Amendment: Please enter the Sequence Listing into the application. **Preliminary Amendment** Prior to calculation of fees, kindly enter:  $\boxtimes$ Preliminary Amendment submitted herewith

do not enter Preliminary Amendment



09/857669 PATENT PATENT OCKET NO. BM45339

The correspondence address for this application is the Customer No. provided below:

## Insert Bar Code Label Here:

25308

13. Fee payment being made at this time is enclosed:

\* Basic filing fee (\$860.00)

860.00

\* Claims in Excess of 20

126.00

\* (7 @ \$18.00)

Independent Claims in Excess of 3

80.00

(1 @ \$80.00)

\* Total Fees enclosed:

\$1066.00

14. The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Account No. 50-0258. This letter is filed in duplicate for accounting purposes.

Respectfully submitted,

Date: June 6, 2001

Eric A. Meade

Registration No. 42,876

for

Allen Bloom

Registration No. 29,135 Attorney for Applicant

**DECHERT** 

Princeton Pike Corporate Center PO Box 5218 Princeton, New Jersey 08543-5218 Allen Bloom (609) 620-3214

Eric A. Meade (609) 620-3248

Fax: (609) 620-3259 Attn.: Allen Bloom, Esq.

(609) 620-3214

C:\WIN98\TEMP.BM45339 - NATIONAL PHASE FILING TRANSMITTAL LTR\_V1.DOC